Why IMU is a multi multi bagger, page-3238

Lets not forget our most recent appointments influence moving forward to the Immugene team..
I found this on his previous employers websit eupon his acquisition a few years ago:

Dr. Shah has more than 20 years of pharmaceutical and biotechnology industry experience in oncology drug development. Before joining WindMIL, he was the Chief Operating Officer of Brooklyn ImmunoTherapeutics, previously known as IRX Therapeutics. Prior to his tenure there, Dr. Shah was the Medical Affairs Lead for Immuno-Oncology at Bristol-Myers Squibb. He also served as Head of Clinical Operations and Development at Ventrus Biosciences before its merger with Assembly Biosciences. Prior to Ventrus, Dr. Shah led the solid tumor development programs and the clinical portfolio and strategic planning function at Celgene. He also led the Oncology Development and Operations activities at FibroGen and Novacea. Dr. Shah began his career at Novartis in the Oncology Early Development Group, leading clinical trials before joining the Medical Sciences Group at Amgen. He received his BS and PharmD degrees from Rutgers University and his MBA from Florida Institute of Technology.

DING DING DING DING DING!!!!!!!!!!!!!!